Artikel
Diagnostic Performance of 1,3-Beta-D-Glucan Serum Screening in Patients after Liver Transplantation
Suche in Medline nach
Autoren
Veröffentlicht: | 13. März 2017 |
---|
Gliederung
Text
Introduction: Liver transplant recipients are at higher risk for developing an invasive fungal infection (IFI). 1,3-beta-d-glucan (BDG) is a fungal serum biomarker that can be used in the diagnosis of IFI. In this study, we evaluated the diagnostic performance of BDG screening in patients receiving a cadaveric liver transplantation.
Methods: Patients who received a cadaveric liver transplant between June 2013 and May 2015 were retrospectively enrolled in this single center study. BDG levels in serum samples were determined by using the Fungitell® assay. BDG levels ≥80 pg/ml were considered as positive. According to the revised EORTC/MSG criteria for IFI, patients’ diseases were classified as proven, probable or no evidence of IFI.
Results: A total of 509 serum samples were obtained from 104 patients during their first inpatient period post transplantation. No patient received antifungal prophylaxis. 11 patients fulfilled criteria for proven or probable IFI. For weeks 1 to 4 after transplantation sensitivity, specificity, Youden index (YI), positive predictive value, negative predictive value and diagnostic odds ratio for a minimum cut off-value of 221 pg/ml (maximum YI) amount 0.55, 0.91, 0.45, 0.43, 0.94 and 12.8, respectively.
Conclusion: BDG screening may be helpful in ruling out IFI in liver transplant recipients.